Generic Medicine Info
Indications and Dosage
Ovarian stimulation regimens for assisted reproduction in infertility
Adult: 250 mcg once daily, starting on day 5 or 6 of ovarian stimulation and continued until ovulation induction.
Renal Impairment
Moderate to severe: Contraindicated.
Hepatic Impairment
Moderate to severe: Contraindicated.
Hypersensitivity to gonadotrophin-releasing hormone (GnRH) or any other GnRH analogue. Moderate to severe renal or hepatic impairment. Pregnancy and lactation.
Special Precautions
Women w/ signs and symptoms of active allergic conditions.
Adverse Reactions
Hypersensitivity reactions including anaphylactoid reactions, headache, nausea, GI abdominal pain, neutrophil count ≥8.3/mm3, gynaecologic abdominal pain, ovarian hyperstimulation syndrome, vag bleeding, inj site reactions, foetal death.
Parenteral/SC: X
Monitoring Parameters
Perform ultrasound to assess follicle size.
Drug Interactions
May require dose adjustment of exogenous gonadotropins when concomitantly used during controlled ovarian hyperstimulation.
Description: Ganirelix competitively blocks the gonadotrophin-release hormone receptors on the pituitary gonadotroph and transduction pathway, resulting to a rapid, reversible suppression of gonadotrophin and luteinising hormone secretion, thus preventing ovulation until the follicles are of adequate size.
Duration: <48 hr.
Absorption: Rapidly absorbed. Bioavailability: Approx 91%. Time to peak plasma concentration: 1.1 hr.
Distribution: Volume of distribution: 43.7 L. Plasma protein binding: 81.9%.
Metabolism: Metabolised via enzymatic hydrolysis to 2 primary metabolites (1-4 and 1-6 peptide).
Excretion: Via faeces (approx 75% as metabolites); urine (approx 22% as unchanged drug). Elimination half-life: Approx 13 hr.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Ganirelix, CID=16130957, (accessed on Jan. 22, 2020)

Store at 25°C. Protect from light.
MIMS Class
Trophic Hormones & Related Synthetic Drugs
ATC Classification
H01CC01 - ganirelix ; Belongs to the class of anti-gonadotropin-releasing hormones. Used in hypothalamic hormone preparations.
Anon. Ganirelix. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 03/12/2015.

Buckingham R (ed). Ganirelix acetate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 03/12/2015.

Ganirelix acetate Injection, Solution (Organon USA Inc.). DailyMed. Source: U.S. National Library of Medicine. Accessed 03/12/2015.

Ganirelix acetate Injection. U.S. FDA. Accessed 03/12/2015.

Joint Formulary Committee. Ganirelix. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 03/12/2015.

McEvoy GK, Snow EK, Miller J et al (eds). Ganirelix acetate. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 03/12/2015.

Disclaimer: This information is independently developed by MIMS based on Ganirelix from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in